Streamex Corp. current report, 19 July 2023

Full document

SEC Filing Summary: BioSig Technologies, Inc. (BSGM)

Business Context and Reporting Period

This Form 8-K was filed on July 19, 2023, by BioSig Technologies, Inc. (BioSig), a Delaware corporation. The report details a material definitive agreement entered into by BioSig AI Sciences, Inc. (BioSig AI), a subsidiary of BioSig. The filing addresses a private placement of equity securities and the issuance of a warrant to a financial advisor.

Key Financial Metrics and Transaction Details

  • Capital Raised: $495,000 aggregate purchase price.
  • Shares Issued: 495,000 shares of BioSig AI common stock at $1.00 per share.
  • Ownership Structure: Following the transaction, BioSig retains approximately 84.5% ownership of BioSig AI.
  • Warrant Issuance: A warrant was issued to Laidlaw & Company (UK) Ltd. for 40,500 shares at an exercise price of $1.00 per share.
  • Warrant Terms: Immediately exercisable; expires five years from issuance.

Note: This filing does not provide consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics for the parent company or the subsidiary.

Material Changes

The primary material change is the dilution of BioSig's ownership in its subsidiary, BioSig AI, from a higher percentage to approximately 84.5% following the private placement. Additionally, the capitalization of BioSig AI has increased by $495,000 in cash proceeds.

Outlook, Risks, and Contingencies

The transaction was executed under exemptions from registration under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933. The filing references a Securities Purchase Agreement containing standard representations, warranties, and covenants. No specific forward-looking guidance, risk factors, or unusual items beyond the standard transaction terms were disclosed in this specific report.

Investor Verification Checklist

  • Verify the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
  • Confirm the exact pre-transaction ownership percentage of BioSig in BioSig AI to calculate precise dilution.
  • Review the engagement agreement with Laidlaw & Company to understand the scope of services provided for the warrant issuance.
  • Check subsequent filings for the use of proceeds from the $495,000 private placement.